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In the present study, we used dual-probe microdialysis to in-
vestigate the effects of intrastriatal perfusion with neurotensin
(NT) on striatal and pallidal glutamate and GABA release. The
role of the pallidal GABAA receptor in the intrastriatal NT-
induced increase in pallidal glutamate release was also
investigated.
Intrastriatal NT (100 and 300 nM) increased striatal gluta-
mate and GABA (100 nM, 155 6 9 and 141 6 6%, respec-
tively; 300 nM, 179 6 8 and 166 6 11%, respectively) release,
as well as pallidal glutamate and GABA (100 nM, 144 6 8 and
130 6 5%; 300 nM, 169 6 9 and 157 6 8%, respectively)
release. These effects were dose-dependently antagonized
by the NT receptor antagonist 2-[(1-(7-chloro-4-quinolinyl)-
5-(2,6-dimethoxy-phenyl)pyrazol-3-yl)carboxylamino]tricyclo)
3.3.1.1.3.7)-decan-2-carboxylic acid (SR48692).
Intrasubthalamic injection of the GABAA receptor antagonist
(2)-bicuculline (10 pmol/100 nl, 30 sec) rapidly increased pal-
lidal glutamate release, whereas the intrastriatal NT-induced
increase in pallidal glutamate release was counteracted by
intrapallidal perfusion with (2)-bicuculline, suggesting that an
increase in striopallidal GABA-mediated inhibition of the
GABAergic pallidal–subthalamic pathway results in an in-
creased glutamatergic drive in the subthalamic–pallidal
pathway.
These results demonstrate a tonic pallidal GABA-mediated
inhibition of excitatory subthalamic–pallidal neurons and
strengthen the evidence for a functional role of NT in the
regulation of glutamate and GABA transmission in the basal
ganglia. The ability of intrastriatal SR48692 to counteract the
NT-induced increase in both striatal and pallidal glutamate and
GABA release suggests that blockade of the striatal NT recep-
tor may represent a possible new therapeutic strategy in the
treatment of those hypokinetic disorders implicated in disor-
ders of the indirect pathway mediating motor inhibition.
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The striatum regulates the activity of the GABAergic projection
neurons of the substantia nigra pars reticulata (SNr) via two main
functional opposing pathways, the direct and indirect pathways
(Albin et al., 1989; Alexander and Crutcher, 1990; Gerfen, 1992).
The former is represented by the striatonigral GABAergic pro-
jection and monosynaptically inhibits the nigrothalamic GABA
pathway, leading to a thalamic disinhibition of the glutamatergic
drive to the cortex and therefore leading to movement initiation,
whereas the latter encompasses a trisynaptic link including (1) a
GABAergic projection from the striatum to the globus pallidus
(GP), (2) a GABAergic projection from the GP to the subtha-
lamic nucleus (STN), and (3) a glutamatergic projection from the
STN to the SNr, which also innervates the GP. Activation of the
striopallidal “link” in the indirect pathway is associated with an
increase in STN glutamatergic input to the SNr and GP, and this
results in changes in both thalamic activity and locomotor behav-
ior opposite to those elicited by activation of the direct pathway
(Albin et al., 1989; Alexander and Crutcher, 1990; Chevalier and
Deniau, 1990).
Neurotensin (NT) is a 13-amino acid peptide (Carraway and
Leeman, 1973) that is widely distributed in the striatum (Jennes
et al., 1982; Quirion et al., 1985; Deutch and Zahm, 1992; Fuxe et
al., 1992a; Castel et al., 1994). The existence of a reciprocal
modulation between neurotensinergic and dopaminergic systems
in several brain areas has been demonstrated by many functional
studies (Nemeroff and Cain, 1985; Blaha et al., 1990; Castel et al.,
1994; Tanganelli et al., 1994; Wagstaff et al., 1996). NT reduces
the affinity of D2 agonist binding sites and possibly their trans-
duction through a receptor–receptor interaction at both presyn-
aptic and postsynaptic levels in the striatum (Agnati et al., 1983;
von Euler and Fuxe, 1987; Fuxe et al., 1992a,b), which provides
the basis for its cataleptic profile (Shibata et al., 1987; Da-Silva et
al., 1989; Shandra et al., 1994). Although most of the studies were
focused on the modulation of the dopaminergic systems by NT,
recent findings suggested that NT interacts with other neuro-
transmitters. In this respect, it was demonstrated that NT is
localized in some striatal GABAergic neurons, and NT receptors
were detected in striatal neurons (Fuxe et al., 1992a). Moreover,
microdialysis studies demonstrated that NT regulates neuronal
elements in the striatum postjunctionally to the afferent dopa-
mine terminals such as striatal glutamatergic afferent terminals
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(Ferraro et al., 1995) and striatal GABAergic efferents (Fuxe et
al., 1992b; O’Connor et al., 1992). These two neurotransmitters
are present in pathways that represent important links in the basal
ganglia–thalamocortical circuit and that provide a neuronal net-
work through which the motor cortex executes motor function.
However, the precise functional role of striatal NT in regulating
glutamate and GABA transmission in the basal ganglia still
remains unclear.
In the present study, the role of striatal NT receptor activation
and blockade in the regulation of striatal and pallidal glutamate
and GABA transmission was investigated.
MATERIALS AND METHODS
Materials. Male adult Sprague Dawley rats (300–350 gm) were purchased
from Stefano Morini (Reggio Emilia, Italy), kept under regular lighting
conditions (12 hr light /dark cycle), and given food and water ad libitum.
NT (Peninsula Laboratories, Belmont, CA) and (2)-bicuculline
methochloride (Sigma, St. Louis, MO) were dissolved in Ringer’s solu-
tion just before testing and used only once. 2-[(1-(7-chloro-4-quinolinyl)-
5-(2,6-dimethoxy-phenyl)pyrazol-3-yl)carboxylamino]tricyclo)
3 . 3 . 1 . 1 . 3.7 ) - decan - 2 - carboxylic acid (SR48692; Sanofi Recherche,
Montpellier, France) was dissolved in dimethylsulfoxide and intraperi-
toneally injected or diluted in the Ringer’s solution (final concentra-
tion of dimethylsulfoxide was ,0.001%). When required, the DMSO
vehicle was perfused in either control animals or in combination with NT
perfusion.
All other chemicals used were of analytical grade and purchased from
Sigma or Merck (Darmstadt, Germany).
Surgery. The animals, kept under halothane anesthesia (1.5% mixture
of halothane and air), were mounted in a David Kopf stereotaxic frame
with the upper incisor bar set at 22.5 mm below the interaural line. After
exposing the skull and drilling two holes, two microdialysis probes of
concentric design (molecular weight cutoff, 20,000 Da; CMA 12; Carne-
gie Medicin) were implanted. One probe was implanted into the right or
the left striatum (outer diameter, 0.5 mm; length of dialyzing membrane,
4 mm), and the other was implanted into the ipsilateral GP (outer
diameter, 0.5 mm; length of dialyzing membrane, 2 mm). The coordi-
nates relative to the bregma were as follows: striatum, anterior (A), 10.3;
lateral (L), 63.1; ventral (V), 28.5; GP, A, 21.3; L, 63.3; V, 28.0
(Paxinos and Watson, 1982). In a final set of experiments, the animals
were implanted with a microdialysis probe into the GP and a stainless
steel guide cannula (22 gauge, C313G; Plastics One, Roanoke, VA) into
an area overlying the ipsilateral STN (A, 23.9; L, 62.2; V, 27.5)
(Rosales et al., 1997). After the implantation, the probes were perma-
nently secured to the skull with methacrylic cement, and 36 hr later the
release experiment was performed.
Experimental protocol. On the day of the release experiment, the
probes were perfused with Ringer’s solution (in mM: Na 1 147, K 1 4,
Ca 21 1.4, Cl 2 156, and glucose 2.7) at a constant flow rate (2 ml /min) by
using a microinfusion pump. The striatal probe was used for both local
perfusion with the NT peptide and its receptor antagonist and the
collection of samples for extracellular glutamate and GABA levels,
whereas the pallidal probe was used for the collection of samples for
extracellular glutamate and GABA levels. When required, the pallidal
probe was also used for the local perfusion with the GABAA receptor
antagonist (2)-bicuculline.
The collection of perfusate samples commenced 300 min after the
onset of perfusion to achieve stable dialysis glutamate levels, and per-
fusates were collected every 30 min. After three stable basal values were
obtained, NT was included into the striatal perfusate medium for 60 min.
This medium was then replaced with the original perfusate, and another
four samples were collected (120 min) from both the striatal and pallidal
probes. When required, the NT receptor antagonist SR48692 (Gully et
al., 1993) was intraperitoneally injected or intrastriatally perfused 20–25
min before the peptide.
When the animals implanted with the guide cannula showed stable
pallidal glutamate levels (three samples), an injection cannula (28 gauge,
C313I; Plastics One) was carefully inserted into the guide cannula to
allow the intrasubthalamic injection of (2)-bicuculline (10 pmol/100 nl,
30 sec) or saline by using an infusion pump. The microdialysis probe
placed in the ipsilateral GP recorded dialysate glutamate release. In view
of previous electrophysiological data (Soltis et al., 1994) demonstrating a
short-lasting effect (10 min) of intrasubthalamic (2)-bicuculline infusion
on pallidal neuronal firing rate, the pallidal samples were, in this set of
experiments, collected every 15 min.
At the end of each experiment, the brain was removed from the skull,
and the position of the probes and the cannula was carefully verified in
30-mm-thick coronal cryostat sections. Only those animals in which both
probes were correctly located were included in this study.
The experimental protocols performed in the present study were
approved by Ministero della Sanita´ (license 111/94-B).
Glutamate and GABA analyses. Endogenous glutamate was quantified
using an HPLC–fluorimetric detection system, including precolumn der-
ivatization o-phtaldialdehyde reagent and a Chromsep 5 (C18) column
(Calo` et al., 1997). The mobile phase consisted of 0.1 M sodium acetate,
10% methanol, and 2.5% tetrahydrofurane, pH 6.5. The limit of detec-
tion for glutamate was 30 fmol /sample.
Endogenous GABA was quantified using an HPLC–electrochemical
detection system, including a precolumn derivatization with an
o-phtaldialdehyde–t-butylthiol reagent and a reverse-phase column
(Nucleosil 3, C18) (Kehr and Ungerstedt, 1989). The mobile phase
consisted of 0.15 M sodium acetate, 0.1 mM EDTA, pH 5.4, and 50%
acetonitrile. The limit of detection for GABA was 20 fmol /sample.
The inclusion of NT or the NT receptor antagonist SR48692 in the
striatal perfusion medium did not alter the pH of the perfusion medium
or interfere with the qualitative and quantitative HPLC assay both of
glutamate and GABA.
Statistical analysis. Data from individual time points are reported as
percentages of the mean of the three basal samples before treatment. The
data were calculated as mean 6 SEM, and the significance with regard to
the peak effects (maximal responses) is shown in the figures. In addition,
the area created by the curve, which mainly reflects the duration of the
effect under the experimental period, was calculated for each animal.
The area values (overall effects) were calculated as percentages of
changes in basal value over time (D basal percentage 3 time) by using the
trapezoidal rule. The statistical analysis was performed by one-way
ANOVA, followed by the Newman–Keuls test for multiple comparisons.
The nonparametric Spearman coefficient was used for correlations.
RESULTS
Effects of intrastriatal perfusion with NT on striatal and
pallidal glutamate release
Basal dialysate glutamate levels in the neostriatum and GP of
control rats were 0.292 6 0.033 and 0.168 6 0.014 mM (n 5 11),
respectively, and remained constant over the duration of the
release experiment (270 min). Intrastriatal perfusion with NT
(100 and 300 nM) produced a rapid and concentration-related
increase in both striatal and pallidal glutamate release (striatum,
155 6 9 and 179 6 8%, respectively; GP, 144 6 8 and 169 6 9%,
respectively).
At the lower 1 and 10 nM concentrations, the peptide did not
affect striatal and pallidal glutamate release (Fig. 1A,B).
Effects of systemic injection and intrastriatal perfusion
of the NT receptor antagonist SR48692 on the
NT-induced increase in striatal and pallidal
glutamate release
Striatal glutamate release
Neither the 0.1 nor the 0.2 mg/kg intraperitoneal dose of the
selective nonpeptide NT receptor antagonist SR48692 affected
basal striatal glutamate levels (Fig. 2A). However, when SR48692
was administered 25 min before intrastriatal NT (100 nM) at the
0.1 and 0.2 mg/kg doses, it dose-dependently counteracted the
increase in glutamate release induced by the peptide (Fig. 2B).
Pallidal glutamate release
SR48692 (0.1 and 0.2 mg/kg, i.p.) did not affect basal glutamate
levels from the GP of the awake rat (Fig. 3A). Similarly to the
striatum, when SR48692 was administered 25 min before intra-
striatal NT (100 nM) at the 0.1 and 0.2 mg/kg doses, it dose-
dependently counteracted the increase in glutamate release in-
duced by the peptide (Fig. 3B).
6978 J. Neurosci., September 1, 1998, 18(17):6977–6989 Ferraro et al. • Neurotensin, Glutamate, and GABA in Basal Ganglia
The effects of the intrastriatal perfusion with SR48692 (100
nM) alone and/or in combination with NT (100 nM) on pallidal
glutamate release were also studied. The intrastriatal application
of the NT receptor antagonist or the vehicle (DMSO, 0.001%) by
themselves did not affect basal pallidal glutamate release. How-
ever, when SR48692 was included in the striatal perfusion me-
dium 20 min before NT (100 nM), it fully counteracted the
peptide-induced enhancement of pallidal glutamate release (Fig.
Figure 1. Effects of intrastriatal perfusion with NT on striatal (A) and pallidal ( B) glutamate release in the awake rat. Solid bars indicate the period
of perfusion with the peptide (60 min). The results are expressed as percentage of the mean of the three basal values before treatment. For absolute
glutamate basal levels, see Results. Each point represents the mean 6 SEM of five to seven animals. Control rats were perfused with normal Ringer’s
perfusion medium throughout the experiment. The histograms of the areas under the curves, calculated as percentage of changes in basal value over time
(D basal percentage 3 time) by using the trapezoidal rule, are shown on the right. **p , 0.01 significantly different from control; °p , 0.05 significantly
different from 100 nM NT according to one-way ANOVA, followed by the Newman–Keuls test for multiple comparisons.
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4). The inclusion of DMSO (0.001%) to the striatal perfusion
medium 20 min before NT (100 nM) did not modify the effects of
the peptide on striatal and pallidal glutamate release (data not
shown).
Effects of intrastriatal neurotensin perfusion on striatal
and pallidal GABA release
Basal striatal and pallidal GABA levels measured in 30 min
dialysate fractions were 18.71 6 2.1 and 9.01 6 0.93 nM (n 5 11),
Figure 2. Effects of intraperitoneal injection of the NT receptor antagonist SR48692 on basal (A) and NT-induced (100 nM) (B) glutamate release from
the striatum of the awake rat. Arrows indicate the injection of SR48692, whereas the solid bar in B indicates the period of perfusion with the peptide (60
min). The results are expressed as percentage of the mean of the three basal values before treatment. Each point represents the mean 6 SEM of five
or six animals. The histograms of the areas under the curves, calculated as percentage of changes in basal value over time (D basal percentage 3 time)
by using the trapezoidal rule, are shown on the right. *p , 0.05, **p , 0.01 significantly different from control; °p , 0.05, °°p , 0.01 significantly different
from 0.1 mg/kg SR48692 plus NT according to one-way ANOVA, followed by the Newman–Keuls test for multiple comparisons.
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respectively, and remained stable over the duration of the exper-
iment. Intrastriatal NT (1, 10, 100, and 300 nM) was associated
with a concentration-dependent increase in both striatal and
pallidal GABA release (striatum, 106 6 6, 100 6 3, 141 6 6, and
166 6 11%, respectively; GP, 107 6 6, 110 6 9, 130 6 5, and
157 6 8%, respectively) (Fig. 5A,B).
Effects of systemic injection of the NT receptor
antagonist SR48692 on the NT-induced increase in
striatal and pallidal GABA release
The selective NT receptor antagonist SR48692 (0.1 and 0.2
mg/kg, i.p.) did not affect basal striatal or pallidal GABA levels,
although a slight decrease in striatal and pallidal GABA release
Figure 3. Effects of intraperitoneal injection of the NT receptor antagonist SR48692 on basal (A) and NT-induced (100 nM) (B) glutamate release from
the GP of the awake rat. Arrows indicate the injection of SR48692. NT was perfused into the striatum for 60 min (solid bar). The results are expressed
as percentage of the mean of the three basal values before treatment. Each point represents the mean 6 SEM of five or six animals. The histograms of
the areas under the curves, calculated as percentage of changes in basal value over time (D basal percentage 3 time) by using the trapezoidal rule, are
shown on the right. **p , 0.01 significantly different from control; °p , 0.05, °°p , 0.01 significantly different from 0.1 mg/kg SR48692 plus NT according
to one-way ANOVA, followed by the Newman–Keuls test for multiple comparisons.
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was observed 120–150 min after SR48692 (0.2 mg/kg, i.p.) injec-
tion (Figs. 6A, 7A). However, when SR48692 was administered 25
min before intrastriatal NT (100 nM) at the 0.1 and 0.2 mg/kg
doses, it dose-dependently counteracted the increase in GABA
release induced by the peptide (Figs. 6B, 7B).
Effects of (2)-bicuculline injected into the subthalamic
nucleus on pallidal glutamate release and (2)-
bicuculline perfused into the globus pallidus on the
NT-induced increase in pallidal glutamate release
In view of the above results and to determine whether the intra-
striatal NT-induced increase in pallidal glutamate release was
mediated by a reduction in the inhibitory striatopallidal–STN
GABA pathway resulting in a disinhibition of the excitatory
STN–SNr and STN–GP glutamate drives, two additional exper-
iments were performed.
First, to support the existence of a tonic GABA inhibition of
the excitatory STN–GP glutamate neurons, the GABAA antag-
onist (2)-bicuculline was directly injected into the STN nucleus,
and the effect on pallidal glutamate release was evaluated. As
shown in Figure 8A, the infusion of (2)-bicuculline (10 pmol/100
nl, 30 sec) into the subthalamic nucleus induced a rapid increase
in pallidal glutamate release, whereas a control injection with
Ringer’s solution was without effect.
Second, the effects of intrapallidal perfusion with (2)-
bicuculline (1 mM) were evaluated on the increase of pallidal
glutamate release induced by the intrastriatal NT (100 nM) per-
fusion. As shown in Figure 8B, the GABAA antagonist perfused
20 min before NT fully counteracted the intrastriatal NT-
induced increase in pallidal glutamate release. When perfused
alone, (2)-bicuculline (1 mM) did not affect pallidal glutamate
release. These results prompted us to further analyze the exis-
tence of a possible correlation between the effects of NT on
pallidal glutamate and GABA release by using the nonparametric
Spearman test. As shown in Figure 9, by evaluating the area
under the curve values, a significant correlation was found.
DISCUSSION
It is well known that the complex neuronal interactions that take
place in the basal ganglia play a crucial role in the regulation of
the motor activity. The GABAergic striatopallidal pathway rep-
resents the first link in the so-called striatal indirect efferent
pathway to the SNr, and its activation is associated with an
enhancement in STN glutamatergic input to the SNr, an increase
in the inhibitory regulation of the motor thalamus, and a reduced
excitatory drive on the motor cortex (Alexander and Crutcher,
1990). Previous studies indicate that NT exerts a modulatory
action on the neuronal transmission in the basal ganglia, partic-
ularly on presynaptic and postsynaptic elements of the nigrostri-
Figure 4. Effects of intrastriatal perfusion with the NT receptor antagonist SR48692 on NT-induced (100 nM) glutamate release from the GP of the
awake rat. NT was perfused into the striatum for 60 min (solid bar), whereas SR48692 was added to the striatal perfusion medium 20 min before the
peptide and maintained until the end of the experiment (open bar). The results are expressed as percentage of the mean of the three basal values before
treatment. Each point represents the mean 6 SEM of five or six animals. The histograms of the areas under the curves, calculated as percentage of
changes in basal value over time (D basal percentage 3 time) by using the trapezoidal rule, are shown on the right. **p , 0.01 significantly different from
control; °°p , 0.01 significantly different from 100 nM SR48692 plus NT according to one-way ANOVA, followed by the Newman–Keuls test for multiple
comparisons.
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Figure 5. Effects of intrastriatal perfusion with NT on striatal (A) and pallidal ( B) GABA release in the awake rat. Solid bars indicate the period of
perfusion with the peptide (60 min). The results are expressed as percentage of the mean of the three basal values before treatment. For absolute GABA
basal levels, see Results. Each point represents the mean 6 SEM of five to seven animals. Control rats were perfused with normal Ringer’s perfusion
medium throughout the experiment. The histograms of the areas under the curves, calculated as percentage of changes in basal value over time (D basal
percentage 3 time) by using the trapezoidal rule, are shown on the right. **p , 0.01 significantly different from control; °p , 0.05, °°p , 0.01 significantly
different from 100 nM NT according to one-way ANOVA, followed by the Newman–Keuls test for multiple comparisons.
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atal dopaminergic pathway (Fuxe et al., 1992b). In the present
study, dual-probe microdialysis was used to investigate the func-
tional role of the striatal NT receptor on striatal and pallidal
amino acid-ergic transmission by monitoring simultaneously al-
terations in glutamate and GABA release induced by the striatal
NT receptor activation and blockade. In addition, in view of the
results obtained, we investigated the role of pallidal GABA reg-
ulation in the STN–GP glutamate pathway.
Extracellular striatal glutamate levels are derived in part from
the terminals of cortical and thalamic afferents, whereas extracel-
Figure 6. Effects of intraperitoneal injection of the NT receptor antagonist SR48692 on basal (A) and NT-induced (100 nM) (B) GABA release from
the striatum of the awake rat. Arrows indicate the injection of SR48692, whereas the solid bar indicates the period of perfusion with the peptide (60 min).
The results are expressed as percentage of the mean of the three basal values before treatment. Each point represents the mean 6 SEM of five or six
animals. The histograms of the areas under the curves, calculated as percentage of changes in basal value over time (D basal percentage 3 time) by using
the trapezoidal rule, are shown on the right. *p , 0.05, **p , 0.01 significantly different from control; °°p , 0.01 significantly different from 0.1 mg/kg
SR48692 plus NT according to one-way ANOVA, followed by the Newman–Keuls test for multiple comparisons.
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lular striatal GABA levels are derived in part from local inter-
neurons and the axon collaterals of the striopallidal and strion-
igral projection neurons (Sirinathsinghji and Heavens, 1989;
Parent and Hazrati, 1995). Extracellular pallidal glutamate levels
are derived from the terminals of the STN–GP pathway, whereas
pallidal GABA levels are derived from the terminals of the
striopallidal pathway or from local axon collaterals of pallidal
GABA projection neurons (Park et al., 1982; Scheel-Kruger,
1986; Pasik et al., 1987; Parent and Hazrati, 1995).
The present results clearly indicate that striatal and pallidal
glutamate and GABA release is increased after striatal NT re-
ceptor activation and provide strong evidence that the increase in
Figure 7. Effects of intraperitoneal injection of the NT receptor antagonist SR48692 on basal (A) and NT-induced (100 nM) (B) GABA release from
the GP of the awake rat. Arrows indicate the injection of SR48692. NT was perfused into the striatum for 60 min (solid bar). The results are expressed
as percentage of the mean of the three basal values before treatment. Each point represents the mean 6 SEM of five or six animals. The histograms of
the areas under the curves, calculated as percentage of changes in basal value over time (D basal percentage 3 time) by using the trapezoidal rule, are
shown on the right. *p , 0.05, **p , 0.01 significantly different from control; °p , 0.05, °°p , 0.01 significantly different from 0.1 mg/kg SR48692 plus
NT according to one-way ANOVA, followed by the Newman–Keuls test for multiple comparisons.
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pallidal glutamate release is mediated via increased excitatory
glutamatergic STN–GP transmission. Furthermore, the counter-
action of these effects by the systemic and local administration of
the NT receptor antagonist SR48692 (Gully et al., 1993; Betan-
cour et al., 1995) suggests that the striatal NT receptor regulates
the indirect pathway in the basal ganglia either directly via so-
matodendritic NT receptors on the GABA neurons and/or indi-
rectly via NT receptors on corticostriatal and/or thalamostriatal
Figure 8. A, Effects of intrasubthalamic injection of the GABAA receptor antagonist (2)-bicuculline on basal glutamate release from the GP of the
awake rat. (2)-Bicuculline (10 pmol/100 nl, 30 sec) or saline (30 sec) was injected (arrow) into the subthalamic nucleus by using an infusion pump.
Control rats were implanted but did not receive any infusion during the experiment. B, Effects of intrapallidal perfusion with the GABAA receptor
antagonist (2)-bicuculline on NT-induced (100 nM) glutamate release from the GP of the awake rat. NT was perfused into the striatum for 60 min (solid
bar), whereas (2)-bicuculline was added to the pallidal perfusion medium 20 min before the peptide and maintained until the end of the experiment
(open bar). The results are expressed as percentage of the mean of the three basal values before treatment. Each point represents the mean 6 SEM of
six to nine animals. The histograms of the areas under the curves, calculated as percentage of changes in basal value over time (D basal percentage 3
time) by using the trapezoidal rule, are shown on the right. **p , 0.01 significantly different from control; °°p , 0.01 significantly different from
(2)-bicuculline plus NT according to one-way ANOVA, followed by the Newman–Keuls test for multiple comparisons.
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glutamate terminals (O’Connor et al., 1992; Ferraro et al., 1995,
1997). Although these neurons have not been extensively shown
to possess NT receptors, this hypothesis is supported by the work
of Masuo et al. (1990), who suggested that a certain proportion of
NT receptors may be located on striatal projection neurons.
Nevertheless, in view of studies (Quirion et al., 1985, 1992)
demonstrating the presence of high-affinity NT receptors primar-
ily on dopaminergic terminals and possibly on cholinergic inter-
neurons in the striatum, it cannot be excluded that the NT-
induced effects observed in the present study can also involve
actions on other transmitters. However, O’Connor et al. (1992)
and Steinberg et al. (1995) have shown that striatal acetylcholine
release is not modulated by NT. Furthermore, the activation of
the high-affinity NT receptor on the dopaminergic terminal by
increasing striatal dopamine release (Fuxe et al., 1992b) would
result in an enhancement of the dopamine D2 receptor-mediated
inhibition of striopallidal GABA release rather than the observed
increase in striopallidal GABA transmission. Together, these
findings suggest that some NT receptors, possibly located on the
striopallidal GABA projection neurons and/or their glutamater-
gic inputs, could mediate the observed effects of intrastriatal NT
on GABA and glutamate release, although other mechanism(s)
cannot be definitively excluded.
The present microdialysis results confirm those of a previous
study that showed that the intrastriatal NT-induced increase in
pallidal GABA release is counteracted by intrastriatal adminis-
tration of the NT receptor antagonist SR48692 (Ferraro et al.,
1997) and go on to show that intrastriatal NT concentration
dependently increases both striatal and pallidal glutamate release.
The finding of a counteraction of the NT-induced increase in
pallidal glutamate release after intrapallidal GABAA receptor
blockade with (2)-bicuculline provides strong evidence that the
NT receptor activation in the striatum regulates pallidal gluta-
matergic transmission via increased striopallidal GABA transmis-
sion, probably by reducing the activity of those GABAergic
neurons projecting to the STN and thus disinhibiting the excita-
tory glutamatergic STN–SNr efferents, which sends axon collat-
erals to the GP (Alexander and Crutcher, 1990) (Fig. 10). The
intrapallidal (2)-bicuculline perfusion was used to antagonize
the intrastriatal NT-induced effects on pallidal glutamate release,
because previous studies demonstrated the role of GABAA re-
ceptor activation in modulating the pallidal output system toward
the STN (Kita, 1992; Amalric et al., 1994). The existence of a
tonic pallidal GABA-mediated inhibition of excitatory STN–GP
neurons is further supported by the demonstration that intra-
STN infusion of (2)-bicuculline induced a significant increase in
pallidal glutamate release. This finding is in line with a previous
electrophysiological study (Soltis et al., 1994), which demon-
strated that the infusion of bicuculline into the STN induced an
increase in the firing rate of pallidal neurons and with the in situ
study of Delfs et al. (1995), who showed that pallidal GAD
mRNA is regulated by an excitatory input from the STN. Finally,
this pallidal GABA–glutamate interaction is strengthened by the
positive correlation found between the effects of NT on pallidal
GABA and glutamate release.
In view of converging evidence suggesting that behavioral
catalepsy in rodents and akinesia in humans is mediated by
increased striopallidal GABA transmission (Scheel-Kruger, 1986;
Drew et al., 1990; Osborne et al., 1994), these findings suggest that
the cataleptic profile of NT (Shibata et al., 1987; Da-Silva et al.,
1989; Shandra et al., 1994) may be explained by its ability to
influence neurotransmission in the indirect striatonigral pathway,
in particular by increasing the excitatory STN–SNr and STN–GP
drives on the inhibitory nigrothalamic pathway, which results in a
reduction of excitatory thalamocortical drive on the (motor)
cortex (De Long, 1990; Amalric et al., 1994). The counteraction
of the NT-induced increase in striatal and pallidal glutamate
release by the NT receptor antagonist SR48692 suggests that NT
receptor blockade in the striatum may be a novel and highly
selective therapeutic approach, in combination with the “classical
therapy,” for the amelioration of extrapyramidal motor disorders
such as Parkinson’s disease. In addition, the fact that these NT-
induced effects are observed at the nanomolar range strengthens
the argument for a physiological role of this neuropeptide in
modulating the motor function via the indirect strionigral
pathway.
In conclusion, these results indicate that in addition to the well
documented evidence for a presynaptic NT–dopamine interac-
tion, striatal NT also operates postsynaptically to the dopamine
afferents by increasing striatal GABA and glutamate, probably
involving an activation of NT receptors located on striatal GABA
cells projecting to the GP and a direct activation of NT receptors
on the striatal glutamate terminals (Ferraro et al., 1995). The
increase in pallidal GABA release probably reflects an activation
of the striopallidal GABA pathway, whereas the increase in
pallidal glutamate release reflects a disinhibition of the excitatory
STN–GP pathway. These findings strengthen the evidence for a
striatal NT receptor-mediated increase in GABA and glutamate
transmission in the basal ganglia, which may contribute to the
pathogenesis of some hypokinetic disorders (Sadoul et al., 1984;
Fernandez et al., 1995). Thus, it may be suggested that striatal NT
receptor blockade, in combination with classical anti-
Parkinsonian drugs, could be helpful in ameliorating extrapyra-
midal hypokinetic motor disorders such as Parkinson’s disease in
which NT transmission may be pathologically increased because
of a loss of inhibitory dopaminergic D2 tone on NT synthesis
(Frey et al., 1986).
Figure 9. A significant positive correlation between intrastriatal NT-
induced (1–300 nM) alterations in pallidal GABA and glutamate release
was found by evaluating the area under the curve values plotted on the y-
and x-axes, respectively. The Spearman correlation coefficient was used.
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